NDA 215446 · Shionogi
Radicava Ors
Edaravone · Oral
Priority reviewOrphanLast checked: Nov 20, 2026Latest source record: May 12, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2022
May 12, 2022
Approved uses
1
Original approval plus efficacy supplements
Registered trials
69
18 Phase 3, 6 recruiting
FAERS reports
1,604
1,191 serious, 462 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect May 5, 2026.
RADICAVA and RADICAVA ORS are indicated for the treatment of amyotrophic lateral sclerosis (ALS). RADICAVA and RADICAVA ORS are indicated for the treatment of amyotrophic lateral sclerosis (ALS). ( 1 )
Mechanism: The mechanism by which RADICAVA and RADICAVA ORS exert their therapeutic effect in patients with ALS is unknown.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- RADICAVA ORS · EDARAVONE 105MG/5ML · SUSPENSION, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Edaravone" as an intervention, any sponsor and status, largest first.
- Treatment of Acute Ischemic STroke With Edaravone Dexborneol II (TASTE-2)Pivotal-lookingCompleted
Beijing Tiantan HospitalAcademic, hospital or other
NCT05249920 · 1,362 participants · Start Mar 18, 2022 · Primary completion Feb 17, 2023
Drug: Edaravone Dexborneol Concentrated Solution for injection; Edaravone Dexborneol placebo · For: Acute Ischemic Stroke; Mechanical Thrombectomy; Edaravone Dexborneol and 1 more
Sites: Beijing, China
- Study of Compound Edaravone Injection for Treatment of Acute Ischemic StrokePivotal-lookingCompleted
Jiangsu Simcere Pharmaceutical Co., Ltd.Industry
NCT02430350 · 1,200 participants · Start May 2015 · Primary completion Dec 2016
Drug: Compound Edaravone Injection; Edaravone Injection · For: Acute Ischemic Stroke
Sites: Beijing, China; Fuzhou, China; Guangzhou, China · 48 sites in all
- Safety and Efficacy of Edaravone Dexborneol for Acute Ischemic StrokePivotal-lookingNot yet recruiting
Yi YangAcademic, hospital or other
NCT06645522 · 1,200 participants (planned) · Start Oct 30, 2024 · Primary completion Oct 30, 2026
Drug: Edaravone dexborneol; Placebo · For: Acute Ischemic Stroke
Sites: Changchun, China
- Sublingual Edaravone Dexborneol for Inter-hospital Transfer Acute Ischemic Stroke (SLEDAIS)Pivotal-lookingNot yet recruiting
Xinqiao Hospital of ChongqingAcademic, hospital or other
NCT07682922 · 1,040 participants (planned) · Start Jul 1, 2026 · Primary completion Jul 1, 2028
Drug: Edaravone dexborneol sublingual tablet; Placebo · For: Acute Ischemic Stroke
Sites: Chongqing, China
- Phase III Clinical Trial of Y-2 Sublingual Tablets in the Treatment of Acute Ischemic StrokePivotal-lookingCompleted
Peking University Third HospitalAcademic, hospital or other
NCT04950920 · 914 participants · Start Jun 28, 2021 · Primary completion Aug 10, 2022
Drug: Y-2 sublingual tablets; d-borneol · For: Stroke
Sites: Beijin, China
- The Efficacy and Safety of Edaravone Dexborneol Sequential Therapy in the Treatment of Patients With AISPivotal-lookingStatus unknown
Simcere Pharmaceutical Co., LtdAcademic, hospital or other
NCT06176781 · 880 participants (planned) · Start Dec 28, 2023 · Primary completion Mar 28, 2025
Drug: Edaravone Dexborneol Sequential Therapy; Placebo · For: Subjects With Acute Ischemic Stroke
- Edaravone and Argatroban Stroke Therapy Study for Acute Ischemic StrokePivotal-lookingCompleted
Combination Therapy for Acute Ischemic Stroke Study GroupAcademic, hospital or other
NCT00153946 · 814 participants · Start Aug 2004 · Primary completion Mar 2008
Drug: Edaravone · For: Stroke
Sites: Suita, Japan
- Treatment of Acute Ischemic Stroke With Edaravone Dexborneol Sublingual Tablets in Small Vessel DiseasePivotal-lookingRecruiting
Peking Union Medical College HospitalAcademic, hospital or other
NCT06674460 · 600 participants (planned) · Start Aug 1, 2025 · Primary completion Oct 1, 2027
Drug: Edaravone Dexborneol Sublingual Tablets; Placebo · For: Cerebral Small Vessel Disease; Ischemic Stroke
Sites: Beijing, China
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- death212
- cerebral infarction99
- amyotrophic lateral sclerosis84
- disease progression74
- drug ineffective63
- off label use53
- dyspnoea51
- muscular weakness50
- fatigue45
- pneumonia45
- diarrhoea44
- condition aggravated41
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 3 |
| 2005 | 3 |
| 2006 | 4 |
| 2007 | 3 |
| 2008 | 2 |
| 2009 | 4 |
| 2010 | 1 |
| 2011 | 3 |
| 2012 | 30 |
| 2013 | 25 |
| 2014 | 18 |
| 2015 | 22 |
| 2016 | 21 |
| 2017 | 45 |
| 2018 | 49 |
| 2019 | 76 |
| 2020 | 42 |
| 2021 | 56 |
| 2022 | 103 |
| 2023 | 194 |
| 2024 | 363 |
| 2025 | 319 |
| 2026 | 218 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Radicava Ors (Edaravone)
2024 spending
$376M
Beneficiaries
3,530
26,703 claims
Per beneficiary
$106,432
$274.41 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $88,869,916 |
| 2023 | $293,678,844 |
| 2024 | $375,705,708 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Pharmacological treatments for vascular dementia: a systematic review and Bayesian network meta-analysis.
Dang C, Wang Q, Zhuang Y, et al. · Front Pharmacol 2024 · Systematic Review
- Edaravone Dexborneol Versus Edaravone Alone for the Treatment of Acute Ischemic Stroke: A Phase III, Randomized, Double-Blind, Comparative Trial.
Xu J, Wang A, Meng X, et al. · Stroke 2021 · Clinical Trial, Phase III, Comparative Study
- Edaravone for Acute Ischemic Stroke: A Systematic Review and Meta-analysis.
Zhao K, Li GZ, Nie LY, et al. · Clin Ther 2022 · Meta-Analysis, Systematic Review
- Edaravone dexborneol versus placebo on functional outcomes in patients with acute ischaemic stroke undergoing endovascular thrombectomy (TASTE-2): randomised controlled trial.
Wang C, Gu H, Huo X, et al. · BMJ 2026 · Randomized Controlled Trial, Multicenter Study
- Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial.
· Lancet Neurol 2017 · Clinical Trial, Phase III, Randomized Controlled Trial
- Efficacy analysis of neuroprotective drugs in patients with acute ischemic stroke based on network meta-analysis.
Li M, Huo X, Chang Q, et al. · Front Pharmacol 2024 · Systematic Review
Sponsor: Shionogi
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.